TPL2/COT/MAP3K8 (TPL2) activation promotes androgen depletion-independent (ADI) prostate cancer growth

PLoS ONE

Volumn 6, Issue 1, 2011, Pages

  Jeong, Joseph H ^a   Bhatia, Ayesha ^a   Toth, Zsolt ^a   Oh, Soohwan ^a   Inn, Kyung Soo ^a   Liao, Chun Peng ^b   Roy Burman, Pradip ^b   Melamed, Jonathan ^c   Coetzee, Gerhard A ^a   Jung, Jae U ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN SERINE THREONINE KINASE; PROTEIN TPL2; UNCLASSIFIED DRUG; MAP3K8 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; ONCOPROTEIN;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OPEN READING FRAME; PHENOTYPE; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; ANIMAL; DISEASE COURSE; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

ANDROGENS; ANIMALS; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MAP KINASE KINASE KINASES; MICE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; UP-REGULATION;

EID: 79251543705     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016205     Document Type: Article

References (51)

1. Coffey DS (1993) Prostate cancer. An overview of an increasing dilemma. Cancer 71: 880-886.
2. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45.
3. Zhou Z, Flesken-Nikitin A, Corney DC, Wang W, Goodrich DW, et al. (2006) Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 66: 7889-7898.
4. Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, et al. (2003) Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A 100: 7841-7846.
5. Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, et al. (2006) Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A 103: 14477-14482.
6. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, et al. (2003) Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4: 223-238.
7. Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, Desai N, et al. (2003) Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 63: 3886-3890.
8. Heemers HV, Tindall DJ (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28: 778-808.
9. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ (2002) Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 62: 1008-1013.
10. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, et al. (2009) In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res 15: 39-47.
11. Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS (2006) Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 66: 10613-10620.
12. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, et al. (2000) Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6: 703-706.
13. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, et al. (2004) HER2/ neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6: 517-527.
14. Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, et al. (2007) Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A 104: 8438-8443.
15. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, et al. (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57: 314-319.
16. Guo Z, Dai B, Jiang T, Xu K, Xie Y, et al. (2006) Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10: 309-319.
17. Craft N, Shostak Y, Carey M, Sawyers CL (1999) A mechanism for hormoneindependent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5: 280-285.
18. Chen S, Xu Y, Yuan X, Bubley GJ, Balk SP (2006) Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci U S A 103: 15969-15974.
19. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, et al. (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944.
20. Isaacs JT (1999) The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 26: 263-273.
21. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, et al. (2002) Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277: 29304-29314.
22. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr., Weber MJ (1999) Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279-284.
23. Jeong JH, Wang Z, Guimaraes AS, Ouyang X, Figueiredo JL, et al. (2008) BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS One 3: e3949.
24. Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, et al. (2007) Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 12: 572-585.
25. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, et al. (1987) The endocrinology and developmental biology of the prostate. Endocr Rev 8: 338-362.
26. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, et al. (2010) Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16: 793-798.
27. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, et al. (2007) Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129: 1065-1079.
28. Yeung F, Li X, Ellett J, Trapman J, Kao C, et al. (2000) Regions of prostatespecific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J Biol Chem 275: 40846-40855.
29. Jia L, Kim J, Shen H, Clark PE, Tilley WD, et al. (2003) Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms. Mol Cancer Res 1: 385-392.
30. Weber MJ, Gioeli D (2004) Ras signaling in prostate cancer progression. J Cell Biochem 91: 13-25.
31. Wu X, Wu J, Huang J, Powell WC, Zhang J, et al. (2001) Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101: 61-69.
32. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4: 209-221.
33. Liao CP, Zhong C, Saribekyan G, Bading J, Park R, et al. (2007) Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 67: 7525-7533.
34. Liao CP, Liang M, Cohen MB, Flesken-Nikitin A, Jeong JH, et al. (2010) Mouse prostate cancer cell lines established from primary and post-castration recurrent tumors. Horm Cancer 1: 44-54.
35. Miyoshi J, Higashi T, Mukai H, Ohuchi T, Kakunaga T (1991) Structure and transforming potential of the human cot oncogene encoding a putative protein kinase. Mol Cell Biol 11: 4088-4096.
36. Patriotis C, Makris A, Bear SE, Tsichlis PN (1993) Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. Proc Natl Acad Sci U S A 90: 2251-2255.
37. Ceci JD, Patriotis CP, Tsatsanis C, Makris AM, Kovatch R, et al. (1997) Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation. Genes Dev 11: 688-700.
38. Belich MP, Salmeron A, Johnston LH, Ley SC (1999) TPL-2 kinase regulates the proteolysis of the NF-kappaB-inhibitory protein NF-kappaB1 p105. Nature 397: 363-368.
39. Beinke S, Deka J, Lang V, Belich MP, Walker PA, et al. (2003) NF-kappaB1 p105 negatively regulates TPL-2 MEK kinase activity. Mol Cell Biol 23: 4739-4752.
40. Sourvinos G, Tsatsanis C, Spandidos DA (1999) Overexpression of the Tpl-2/ Cot oncogene in human breast cancer. Oncogene 18: 4968-4973.
41. Wang XD, Wang BE, Soriano R, Zha J, Zhang Z, et al. (2007) Expression profiling of the mouse prostate after castration and hormone replacement: implication of H-cadherin in prostate tumorigenesis. Differentiation 75: 219-234.
42. Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L, et al. (2006) PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate 66: 1329-1338.
43. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, et al. (2005) LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437: 436-439.
44. Choi HS, Kang BS, Shim JH, Cho YY, Choi BY, et al. (2008) Cot, a novel kinase of histone H3, induces cellular transformation through up-regulation of cfos transcriptional activity. FASEB J 22: 113-126.
45. Balistreri CR, Colonna-Romano G, Lio D, Candore G, Caruso C (2009) TLR4 polymorphisms and ageing: implications for the pathophysiology of age-related diseases. J Clin Immunol 29: 406-415.
46. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M (2010) B-cellderived lymphotoxin promotes castration-resistant prostate cancer. Nature 464: 302-305.
47. Gatti G, Quintar AA, Andreani V, Nicola JP, Maldonado CA, et al. (2009) Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer. Prostate 69: 1387-1397.
48. Achanzar WE, Brambila EM, Diwan BA, Webber MM, Waalkes MP (2002) Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. J Natl Cancer Inst 94: 1888-1891.
49. Lee KM, Lee KW, Bode AM, Lee HJ, Dong Z (2009) Tpl2 is a key mediator of arsenite-induced signal transduction. Cancer Res 69: 8043-8049.
50. Das S, Cho J, Lambertz I, Kelliher MA, Eliopoulos AG, et al. (2005) Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner. J Biol Chem 280: 23748-23757.
51. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, et al. (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54: 2577-2581.